| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC1172 |
| Trial ID | NCT00004870 |
| Disease | Colorectal Cancer |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Co-treatment | irinotecan hydrochloride |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Phase I/II, Pharmacokinetic, and Biologic Correlative Study of G3139, NSC # 683428 (Phosphorothioate Antisense Oligonucleotide Directed to Bcl-2) and Irinotecan in Patients With Metastatic Colorectal Cancer |
| Year | 2013 |
| Country | United States |
| Company sponsor | The University of Texas Health Science Center at San Antonio |
| Other ID(s) | CDR0000067529|SACI-IDD-98-32|UTHSC-IDD-98-32|NCI-T98-0094 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||